A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose

Therapeutic Advances in Psychopharmacology

Volumn 3, Issue 3, 2013, Pages 151-161

  Taylor, David ^a   Lenox Smith, Alan ^b   Bradley, Andrew ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

cardiovascular; depression; duloxetine; mortality; primary care; suicide; venlafaxine

Indexed keywords

DULOXETINE; VENLAFAXINE;

ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; DEPRESSION; DISEASE ASSOCIATION; DRUG OVERDOSE; DRUG SAFETY; FATALITY; GENERAL PRACTITIONER; GENERALIZED ANXIETY DISORDER; HUMAN; LONG TERM CARE; MORTALITY; OUT OF HOSPITAL CARDIAC ARREST; PATIENT SAFETY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QT INTERVAL; QT PROLONGATION; RISK BENEFIT ANALYSIS; SELF POISONING; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; UNITED KINGDOM;

EID: 84997860386     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312472890     Document Type: Article

References (65)

1. Acharya N. Rosen A. Polzer J. D’Souza D. Perahia D. Cavazzoni P. et al. (2006) Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 26: 587–594.
2. Allgulander C. Nutt D. Detke M. Erickson J. Spann M. Walker D. et al. (2008) A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol 22: 417–425.
3. Anderson M. Al-Khatib S. Roden D. Califf R. (2002) Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 144: 769–781.
4. Bebbington P. Brugha T. Coid J. Crawford M. Deverill C. D’Souza A. et al. (2009) Adult Psychiatric Morbidity in England, 2007. Results of a household survey. London: The NHS Information Centre for Health and Social Care.
5. Bergen H. Murphy E. Cooper J. Kapur N. Stalker C. Waters K. et al. (2010) A comparative study of non-fatal self-poisoning with antidepressants relative to prescribing in three centres in England. J Affect Disord 123: 95–101.
6. Bosse G. Spiller H. Collins A. (2008) A fatal case of venlafaxine overdose. J Med Toxicol 4: 18-20.
7. Buckley N. McManus P. (2002) Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325: 1332–1333.
8. Chan A. Gunja N. Ryan C. (2010) A comparison of venlafaxine and SSRIs in deliberate self-poisoning. J Med Toxicol 6: 116–121.
9. Colbridge M. Volans G. (1999) Venlafaxine in oversdose – experience of the national poisons information service (London centre). J Toxicol Clin Toxicol 37: 383.
10. Desai M. Li L. Desta Z. Malik M. Flockhart D. (2003) Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 55: 511–517.
11. Detke M. Iyengar S. Henck J. (2005) Cardiovascular effects of duloxetine: preclinical and clinical findings. In: Proceedings of the American Collage of Neuropsychopharmacology 44th Annual Meeting, Waikoloa, HI, 11–15 December 2005.
12. Entsuah R. (2001) Venlafaxine/venlafaxine XR for suicidal ideation World J Biol Psychiatry 2: 331S.
13. Fossa A. Gorczyca W. Wisialowski T. Yasgar A. Wang E. Crimin K. et al. (2007) Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. J Pharmacol Toxicol Methods 55: 78–85.
14. Gibbons R. Brown C. Hur K. Davis J. Mann J. (2012) Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 69: 580–587.
15. Hawton K. Bergen H. Simkin S. Cooper J. Waters K. Gunnell D. et al. (2010) Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 196: 354–358.
16. Henry J. (1989) A fatal toxicity index for antidepressant poisoning. Acta Psychiatr Scand Suppl 354: 37–45.
17. Henry J. (1993) Debits and credits in the management of depression. Br J Psychiatry Suppl (20): 33–39.
18. Henry J. Antao C. (1992) Suicide and fatal antidepressant poisoning. Eur J Med 1: 343–348.
19. Hojer J. Hulting J. Salmonson H. (2008) Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol (Phila) 46: 336–337.
20. Howell C. Wilson A. Waring W. (2007) Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 64: 192–197.
21. Ilyas S. Moncrieff J. (2012) Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. Br J Psychiatry 200: 393–398.
22. Isbister G. (2009) Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol 67: 572–576.
23. Jick H. Kaye J. Jick S. (2004) Antidepressants and the risk of suicidal behaviors. JAMA 292: 338–343.
24. Kelly C. Dhaun N. Laing W. Strachan F. Good A. Bateman D. (2004) Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 42: 67–71.
25. Khalifa M. Daleau P. Turgeon J. (1999) Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 291: 280–284.
26. Kruithof M. Bruins N. van Roon E. (2011) Coma after overdose with duloxetine. Ann Pharmacother 45: e5.
27. Lawrenson R. Tyrer F. Newson R. Farmer R. (2000) The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 59: 149–157.
28. Letsas K. Korantzopoulos P. Pappas L. Evangelou D. Efremidis M. Kardaras F. (2006) QT interval prolongation associated with venlafaxine administration. Int J Cardiol 109: 116–117.
29. Martinez C. Assimes T. Mines D. Dell'aniello S. Suissa S. (2010) Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ 340: c249.
30. Mbaya P. Alam F. Ashim S. Bennett D. (2007) Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol 22: 129–133.
31. McAllister-Williams R. Foran K. Forrest S. Ingram G. McMahon L. Taylor M. et al. (2006) Prescribing of venlafaxine and dosulepin in primary care. J Psychopharmacol 20: 868.
32. MHRA (2004) Medicines and Healthcare Products Regulatory Agency. Available at: http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON002060 (accessed 16 December 2012).
33. MHRA (2006) Updated prescribing advice for venlafaxine (Efexor/Efexor XL). Medicines and Healthcare Products Regulatory Agency. Available at: http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2023842.pdf (accessed 16 December 2012).
34. MHRA (2007) Antidepressants: suicidal behaviour. Medicines and Healthcare Products Regulatory Agency. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON079102 (accessed 16 December 2012).
35. MHRA (2010a) Fluoxetine: possible small risk of congenital cardiac defects. Medicines and Healthcare Products Regulatory Agency. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON091089 (accessed 16 December 2012).
36. MHRA (2010b) S.S.R.I.s and S.N.R.I.s: risk of persistent pulmonary hypertension in the newborn. Medicines and Healthcare Products Regulatory Agency. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085130 (accessed 16 December 2012).
37. MHRA (2010c) Antidepressants: risk of fractures. Medicines and Healthcare Products Regulatory Agency. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085136 (accessed 16 December 2012).
38. MHRA (2011) Citalopram and escitalopram: QT interval prolongation – new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Medicines and Healthcare Products Regulatory Agency. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137769 (accessed 16 December 2012).
39. MHRA (2012) Drug Analysis Prints (DAPS). Medicines and Healthcare Products Regulatory Agency. Available at: http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/YellowCarddata/Druganalysisprints/index.htm?secLevelIndexChar=Dq%20-%20Du#retainDisplay (accessed 16 December 2012).
40. Menchetti M. Gozzi B. Saracino M. Mercolini L. Petio C. Raggi M. (2009) Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. World J Biol Psychiatry 10: 385–389.
41. Mines D. Hill D. Yu H. Novelli L. (2005) Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 14: 367–372.
42. Moller H. Baldwin D. Goodwin G. Kasper S. Okasha A. Stein D. et al. (2008) Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci 258(Suppl. 3): 3–23.
43. Moore M. Yuen H. Dunn N. Mullee M. Maskell J. Kendrick T. (2009) Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 339: b3999.
44. Morgan O. Griffiths C. Baker A. Majeed A. (2004) Fatal toxicity of antidepressants in England and Wales, 1993–2002. Health Stat Q (23): 18–24.
45. National Health Service Business Services Authority (2011) Available at: http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/PPDPrescribingAnalysisCharts/CNS_Dec_2011_National.pdf (accessed 16 December 2012).
46. National Health Service Information Centre for Health and Social Care (2011). Available at: http://www.ic.nhs.uk/pubs/quarterlypcajanmarch11 (accessed 16 December 2012).
47. NICE (2010) The Treatment and Management of Depression in Adults. NICE Clinical Guideline 90. London: National Institute for Health and Clinical Excellence.
48. NICE (2011) Generalised Anxiety Disorder and Panic Disorder (With or Without Agrophobia) in Adults: Management in Primary, Secondary and Community Care (Partial Update). National Clinical Guideline 113. London: National Institue for Health and Clinical Excellence.
49. Ostler K. Thompson C. Kinmonth A. Peveler R. Stevens L. Stevens A. (2001) Influence of socio-economic deprivation on the prevalence and outcome of depression in primary care: the Hampshire Depression Project. Br J Psychiatry 178: 12–17.
50. Papakostas G. Fava M. Thase M. (2008) Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 63: 699–704.
51. Perahia D. Quail D. Desaiah D. Corruble E. Fava M. (2008) Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry 69: 95–105.
52. Perahia D. Quail D. Desaiah D. Montejo A. Schatzberg A. (2009) Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res 43: 512–518.
53. Romera I. Perez V. Manchon J. Schacht A. Papen R. Neuhauser D. et al. (2012) Early switch strategy in patients with major depressive disorder: a double-blind, randomized study. J Clin Psychopharmacol 32: 479–486.
54. Rose J. Unis A. (2000) A mortality index for postmarketing surveillance of new medications. Am J Emerg Med 18: 176-179.
55. Rubino A. Roskell N. Tennis P. Mines D. Weich S. Andrews E. (2007) Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 334: 242.
56. Rudolph R. Derivan A. (1996) The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 16(3 Suppl. 2): 54S-59S; discussion 59S–61S.
57. Serafimovski N. Thorball N. Asmussen I. Lunding M. (1975) Tricyclic antidepressive poisoning with special reference to cardiac complications. Acta Anaesthesiol Scand Suppl 57: 55–63.
58. Smith D. Dempster C. Glanville J. Freemantle N. Anderson I. (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396–404.
59. Thase M. Pritchett Y. Ossanna M. Swindle R. Xu J. Detke M. (2007) Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 27: 672–676.
60. Trivedi M. Rush A. Wisniewski S. Nierenberg A. Warden D. Ritz L. et al. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28–40.
61. Waring W. Graham A. Gray J. Wilson A. Howell C. Bateman D. (2010) Evaluation of a QT nomogram for risk assessment after antidepressant overdose. Br J Clin Pharmacol 70: 881–885.
62. Weeke P. Jensen A. Folke F. Gislason G. Olesen J. Andersson C. et al. (2012) Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther 92: 72–79.
63. Wernicke J. Lledo A. Raskin J. Kajdasz D. Wang F. (2007) An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 30: 437–455.
64. White N. Litovitz T. Clancy C. (2008) Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol 4: 238–250.
65. Whyte I. Dawson A. Buckley N. (2003) Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96: 369–374.